Driven by executive orders signed by U.S. President Biden, FDA regulations for medical devices, and the enactment of the ...
The draft guidance outlines the testing and clinical evidence manufacturers should include when seeking authorization for ...
FDA issued draft guidance outlining premarket submission recommendations for robotically-assisted surgical devices, ...
Please provide your email address to receive an email when new articles are posted on . The guidelines address issues related to development and prescription of non-opioid pain drugs. They are part of ...
Silver Spring, MD, Sept. 21, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued a direct final rule ...
On July 13, 2026, the U.S. Food and Drug Administration (“FDA” or “Agency”) finalized its guidance on “Psychedelic Drugs: Considerations for Clinical Investigations,” replacing the June 2023 draft ...
The US Food and Drug Administration (FDA) has released a draft guidance detailing how manufacturers should address Form 483 observations following a drug good manufacturing practice (GMP) inspection.
Rulemaking advances reforms sought by Humane World for Animals and Humane World Action Fund to make animal tests the ...
The US Food and Drug Administration (FDA) has issued a pair of draft guidance documents aimed at guiding the selection of proprietary names for prescription and non-prescription drugs. The best ...
Because fresh-cut produce doesn’t undergo a final step to eliminate harmful pathogens, the agency’s recommendations emphasize preventing contamination throughout the production process.
Please provide your email address to receive an email when new articles are posted on . The FDA frequently identifies uncertainties about newly approved cancer drugs, but they are often omitted in ...
The Food and Drug Administration released draft guidance Sept. 24 that includes recommendations on non-clinical testing, ...